Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel,
carboplatin and bevacizumab as first-line treatment in patients with locally advanced or
metastatic nonsquamous non-small cell lung cancer